Market research

AVTX Avalo Therapeutics Inc

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 865M
P/E ratio: Not available
Analyst target: 44.0833
Dividend yield: Not available
Beta: 0.79

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US05338F3064
Market cap: 865M
P/E ratio: Not available
Analyst target: 44.0833
Dividend yield: Not available
Beta: 0.79

About

About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about AVTX.

AVTX Avalo Therapeutics Inc

Price & volume

Company facts

About Avalo Therapeutics Inc

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet